The stock is holding up well. I reckon it might take another 2-4 quarterly reports before we get a clearer picture on cash burn rate. So far revenue look promising.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%